All In Biotech

Drug Trial Radar · NCT07186413

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

A Multicenter, Randomized, Double-blinded, Parallel-group, Vehicle-controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 561 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

561

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • TrifaroteneDrug

    Trifarotene cream applied QD topically.

  • Vehicle CreamDrug

    Vehicle cream applied QD topically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Investigator Global Assessment (IGA) Success (Face only) at Week 12Time frame: Baseline to Week 12
  2. Change from Baseline to Week 12 in Facial Non-inflammatory Lesion CountTime frame: Baseline to Week 12
  3. Change from Baseline to Week 12 in Facial Inflammatory Lesion CountTime frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Galderma Research & Development Site #5378

    Shanghai, Jing'an District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.